tradingkey.logo
tradingkey.logo

Biogen raises annual profit estimates on strong demand for rare disease drugs

ReutersJul 31, 2025 10:08 AM

- Biogen BIIB.O raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as Skyclarys to offset declining sales of its older multiple sclerosis drugs.

On an adjusted basis, Biogen expects 2025 adjusted per-share profit between $15.50 and $16.00, compared with its previous forecast of between $14.50 and $15.50.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI